Hanmi Pharmaceutical Terminates Technology Export Contract for Anticancer Drug From 10 Years Ago… Reclaims Rights
3 Articles
3 Articles
(Seoul = Yonhap News) Reporter Park Sang-hyun = Hanmi Pharmaceutical [128940], which licensed the targeted anticancer drug 'Belvarafenib' (HM95...) to Genentech, a subsidiary of Roche Group, in 2016
Hanmi Pharmaceutical is regaining the rights to 'Belvarafenib (HM95573),' a targeted anticancer drug candidate that it licensed to Genentech 10 years ago. This follows Genentech's notification of contract termination and the return of rights. However, Hanmi Pharmaceutical maintains that this announcement is a foreseen procedure for contract termination, given that Genentech officially announced the discontinuation of development several years ag…
Hanmi Pharmaceutical Terminates Belvarafenib Technology Transfer Agreement… Genentech Returns Rights
The contract for the targeted anticancer drug Belvarafenib, which Hanmi Pharmaceutical licensed to Genentech, is being terminated.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
